RAIN News and Press, Rain Therapeutics Inc. From 11/04/22

Rain Therapeutics ( NASDAQ: RAIN ) priced a registered offering to raise ~$50M in gross proceeds. The company is offering ~6.86M common shares and ~1.72M shares of non-voting common stock, at $5.83 per share. Rain added that the shares of non-voting common stock ar...

Rain Therapeutics ( NASDAQ: RAIN ) said its drug milademetan showed response and antitumor activity in preliminary data from a phase 2 basket trial. The phase 2 study, dubbed MANTRA-2, is evaluating milademetan (RAIN-32) monotherapy in patients with advanced or...

NEWARK, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN) (Rain), a late-stage biotechnology company developing precision oncology therapeutics, today announced the pricing of a registered offering of 6,861,080 shares of common stock and 1,715,250 shares of n...

- Two patients exhibited an unconfirmed partial response at their first scan, and two additional patients saw promising tumor regression activity out of ten efficacy evaluable patients, demonstrating monotherapy activity of milademetan in MDM2-amplified patients - - Drug safety ...

Ortho delivers technicians specs in seconds in an intuitive, portable, hands-free solution Las Vegas, NV - ( NewMediaWire ) - November 01, 2022 - Today at the 2022 Automotive Aftermarket Products Expo (AAPEX) RAIN Technology Inc. announced the public launch of “Ortho, ...

NEWARK, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 comp...

NEWARK, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that react...

NEWARK, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that react...

Rain Therapeutics Inc. (RAIN) Q2 2022 Earnings Conference Call August 4, 2022 5:00 PM ET Company Participants Bob Yedid – LifeSci Advisors Avanish Vellanki – Chief Executive Officer Nelson Cabatuan – Senior Vice President of Finance Bob D...

Image source: The Motley Fool. Rain Therapeutics Inc. (NASDAQ: RAIN) Q2 2022 Earnings Call Aug 04, 2022 , 5:00 p.m. ET Operator Continue reading For further details see: Rain Therapeutics Inc. (RAIN) Q2 2022 Earnings Call Transcript